相似文献
1
Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model.
Cancer Discov. 2025 Jan 13;15(1):162-178. doi: 10.1158/2159-8290.CD-24-0489.
2
Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer.
Sci Transl Med. 2024 Aug 28;16(762):eadj9366. doi: 10.1126/scitranslmed.adj9366.
3
Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy.
Clin Cancer Res. 2025 Jul 1;31(13):2663-2674. doi: 10.1158/1078-0432.CCR-24-4049.
4
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.
Sci Transl Med. 2024 Oct 23;16(770):eado2402. doi: 10.1126/scitranslmed.ado2402.
5
Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
J Immunother Cancer. 2019 May 22;7(1):132. doi: 10.1186/s40425-019-0601-5.
6
Rationally designed anti-autophagy nanosystems for reversing the immunosuppressive network in the tumor environment.
Nanomedicine (Lond). 2025 Jun;20(12):1429-1440. doi: 10.1080/17435889.2025.2508133. Epub 2025 May 22.
7
Pancreatic STAT5 activation promotes Kras-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer.
Gut. 2024 Oct 7;73(11):1831-1843. doi: 10.1136/gutjnl-2024-332225.
8
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
Mol Cancer. 2025 Mar 13;24(1):76. doi: 10.1186/s12943-025-02288-9.
9
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.
Cancer Res Commun. 2024 Jun 21;4(6):1548-1560. doi: 10.1158/2767-9764.CRC-24-0172.
10
Unveiling the intriguing relationship: oncogenic KRAS, morphological shifts, and mutational complexity in pancreatic mucinous cystic neoplasms.
J Pathol. 2025 Apr;265(4):401-407. doi: 10.1002/path.6397. Epub 2025 Feb 5.
引用本文的文献
1
Pancreatic ductal adenocarcinoma: the Everest of cancer biology.
J Clin Invest. 2025 Jul 15;135(14). doi: 10.1172/JCI191936.
2
A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma.
Cancer Discov. 2025 Aug 4;15(8):1717-1739. doi: 10.1158/2159-8290.CD-24-1425.
3
Response and Resistance to RAS Inhibition in Cancer.
Cancer Discov. 2025 Jul 3;15(7):1325-1349. doi: 10.1158/2159-8290.CD-25-0349.
4
Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting.
Cancers (Basel). 2025 Apr 7;17(7):1246. doi: 10.3390/cancers17071246.
5
T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC.
Cancer Discov. 2025 Mar 7. doi: 10.1158/2159-8290.CD-24-1475.
本文引用的文献
1
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Nature. 2024 May;629(8013):927-936. doi: 10.1038/s41586-024-07379-z. Epub 2024 Apr 8.
2
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS.
J Med Chem. 2024 Jan 25;67(2):1147-1167. doi: 10.1021/acs.jmedchem.3c01622. Epub 2024 Jan 10.
3
The cancer-immunity cycle: Indication, genotype, and immunotype.
Immunity. 2023 Oct 10;56(10):2188-2205. doi: 10.1016/j.immuni.2023.09.011.
4
KRAS inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 T cells.
Cancer Cell. 2023 Sep 11;41(9):1606-1620.e8. doi: 10.1016/j.ccell.2023.07.002. Epub 2023 Aug 24.
5
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.
Nature. 2023 Jul;619(7968):160-166. doi: 10.1038/s41586-023-06123-3. Epub 2023 May 31.
6
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10.
7
Adagrasib in Advanced Solid Tumors Harboring a Mutation.
J Clin Oncol. 2023 Sep 1;41(25):4097-4106. doi: 10.1200/JCO.23.00434. Epub 2023 Apr 26.
8
Pancreatic cancer: Advances and challenges.
Cell. 2023 Apr 13;186(8):1729-1754. doi: 10.1016/j.cell.2023.02.014.
9
Arginase 1 is a key driver of immune suppression in pancreatic cancer.
Elife. 2023 Feb 2;12:e80721. doi: 10.7554/eLife.80721.
10
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.
Nat Cancer. 2023 Jan;4(1):62-80. doi: 10.1038/s43018-022-00500-z. Epub 2022 Dec 30.
Zotero 插件